WO1992016209A1 - Granules and veterinary compositions comprising a water-soluble complex of flumequine - Google Patents
Granules and veterinary compositions comprising a water-soluble complex of flumequine Download PDFInfo
- Publication number
- WO1992016209A1 WO1992016209A1 PCT/HU1992/000013 HU9200013W WO9216209A1 WO 1992016209 A1 WO1992016209 A1 WO 1992016209A1 HU 9200013 W HU9200013 W HU 9200013W WO 9216209 A1 WO9216209 A1 WO 9216209A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- flumequine
- weight
- granules
- water
- granulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Definitions
- the invention relates to granules comprising a water- soluble complex of flumequine, as .veil as to a process for the pre par it ion of such granules.
- the invention also relates to veterinary compositions produced from the granules according to the invention.
- flumequine (6,7-dihydro-9-fluoro-5-methyl-1-oxo-1H,5H-benzo-quinolysine-2-carboxylic acid) is an effective antimicrobial agent, highly active against various microorganisms, such as Aeromonas, Escherichia coli, Proteus, Klebsiella, Salmonella and Ihiterobacter species
- Flumequine is, however, only spairingly soluble in water, which renders difficult to convert it into pharmaceutical and veterinary compositions and also restricts its therapeutic use. According to French patent No. 2,453,647 these, difficulties are overcome. by converting flumequine into pharmaceutical compositions in admixture with sodium carbonate; thus the resulting compositions comprise flumequine as its water-soluble sodium salt. According to the cited reference a water-soluble powder mixture comprising
- flumequine 3-10.5 % by weight of flumequine can be prepared by admixing flumequine with sodium carbonate and lactose. Over these powders additional pharmaceutical compositions, such as tablets, injectable aqueous suspensions and ointments, are also mentioned in the cited reference; these composi tions are prepared by methods conventionally applied in pharmacotechnology.
- these complexes are much more suitable for injection or oral administration than the known alkaline flumequine salts, and can be combined unrestrictedly with alkalisensitive substance s .
- the granulation technique applied according to the invention ensures, on one hand, the homogeneity of the admixed components, and, on the other hand, provides the flumequine complex as a product easy to handle and particularly suitable for processing into a veterinary composition.
- the invention relates to granules comprising a water-soluble complex of flumequine formed with polyvinyl pyrrolidone, an amino acid monomer or polymer containing basic group (s) or urea.
- flumequine is admixed with 5-55 % by weight, calculated for the weight of flumequine, of polyvinyl pyrrolidone or an amino acid monomer or polymer containing basic group (s) or with 20-100 % by weight, calculated xor the weight ox flumequine, of urea, and optionally with a known pharmacotechnological granulation aid, and the mixture is subjected to wet granulation.
- flumequine is present as its complex formed with the complexing agent applied, i.e. with polyvinyl pyrrolidone, an amino acid monomer or polymer containing basic grou ⁇ (s) or urea.
- the complexing agent applied i.e. with polyvinyl pyrrolidone, an amino acid monomer or polymer containing basic grou ⁇ (s) or urea.
- Amino acid monomers or polymers containing basic grou ⁇ (s), utilized as complexing agents are amino
- acids which contain over the -NH 2 group characteristic of such compounds at least one further nitrogen-containing basic group, such as one additional amino group, too.
- these amino acids are lysine and arginine.
- an amino acid polymer containing basic group(s) refers to oligomsrs and polymers formed from these amino acids by peptide bonds.
- the mass to be granulated may also contain one or more known pharmacotecnnologieal granulation aid.
- These granulation aids may be substances for inhibiting adhesion and substances for improving distribution.
- the substances for inhibiting adhesion are silicon dioxides with high specific surface area (such as Aerosil) and magnesium stcarate.
- As substances for improving distribution pharmaceutically acceptable water-soluble neutral pcrticulatc solids can be applied, characteristic representatives of which are sugars (such as lactose and glucose) and polysaccharides (such as various starch types).
- sugars such as lactose and glucose
- polysaccharides such as various starch types
- a granulation aid particularly if polyvinyl pyrrolidone or a basic amino acid polymer is applied as complexing agent. If a granulation aid is also present in the mass to be granulated, its amount may be e.g. 1-100% by weight, calculated for the weight of flumequine.
- Granules are prepared according to the invention by any of the wet granulation methods well known in pharmacotcchnology.
- Pharmaceutically acceptable inorganic or organic liquids such as water or an alcohol, can be utilised as granulating liquids.
- the total amount or a part of the complexing agent and/or of the granulation aid is admixed to the mass to be granulated as a solution formed with the granulating liquid.
- the mass to be granulated may have typically e.g. one of the following compositions:
- the granules according to the invention may be applied directly for veterinary purposes, e.g. they can be dissolved in the drinking water of animals. If
- the granules according to the invention can be converted into veterinary compositions, such as powder mixtures, tablets, capsules, injectuble compositions etc., by conventional phermacotechnological opera tions, utilizing conventional veterinary carriers, diluents and/or other auxiliary agents (such as surfactants).
- veterinary compositions can be applied to advantage e.g. for individual treatment or for the treatment of a smaller population.
- the invention also relates to such veterinary compositions as well as to their preparation.
- the veterinary compositionc according to the invention may also comprise adjuvants.
- Preferred representatives of adjuvants are bactoriolytic enzymes which facilitate flumequine to reach its point of attack, i.e. to reach the infecting microorganism.
- the known veterinary compositions comprising flumequine as its alkaline salt cannot be combined with such enzymes which arc characteristic representatives of alkali-sensitive substances.
- adjuvant e.g. lysosimc or an acid addition salt thereof can be applied.
- the veterinary compositions according to the invention may comprise an adjuvant generally in an amount ox 0.5-10 % by weight, preferably 1-3% by weight, calculated for the weight of the composition.
- flumequine can not only be converted into a water-soluble form
- Granules are prepared from the following components
- the half of polyvinyl pyrrolidine is added to the pre -homogenized mixture of the further components as a 20 % by weight ethanol solution.
- the granules are prepared by fluidisation technique.
- the granules prepared according to Example 1 are homogenized in a drum with 129.35 kg of lactose. A powder mixture suitable for veterinary purposes is obtained.
- Granules are prepared as described in Example 1 from the following components:
- Example 2 One proceeds as described in Example 1 with the difference that water is used as granulating liquid and the granules are prepared from the following components: flumequine 10.0 kg
- Example 2 One proceeds as described in Example 1 with the difference that an aqueous gel of potato starch is used as granulating liquid and the granules are prepared from the following components:
- Group II 5 days' treatment with a composition according to French patent Ho. 2,453,647 comprising flumequine as its sodium salt, at a therapeutic level of 12 mg/kg
- Group III 5 days treatment with a composition according to Example 2 at a therapeutic level of 10 mg/kg
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU841/91 | 1991-03-14 | ||
HU84191A HU206975B (en) | 1991-03-14 | 1991-03-14 | Process for producing granulation and veterinary composition comprising water-soluble flumequine complex |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992016209A1 true WO1992016209A1 (en) | 1992-10-01 |
Family
ID=10951644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU1992/000013 WO1992016209A1 (en) | 1991-03-14 | 1992-03-13 | Granules and veterinary compositions comprising a water-soluble complex of flumequine |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0575439A1 (en) |
HU (1) | HU206975B (en) |
WO (1) | WO1992016209A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997009036A2 (en) * | 1995-09-01 | 1997-03-13 | Euro-Celtique S.A. | Improved pharmaceutical ion exchange resin composition |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2049420A (en) * | 1979-04-10 | 1980-12-31 | Riker Laboratories Inc | Veterinary medicament based on benxoquinolizine carboxylic acids and their derivatives |
EP0100168A2 (en) * | 1982-07-06 | 1984-02-08 | Alan George Rogerson | Processes for preparing tablets by a modified 'wet-granulation' technique |
WO1987003509A1 (en) * | 1985-12-10 | 1987-06-18 | Cerwen Erik Audunn | Method for the assembly of polar-nonpolar-polar proteolipid membranes |
EP0261426A1 (en) * | 1986-08-28 | 1988-03-30 | The Du Pont Merck Pharmaceutical Company | Freeze-dried pharmaceutical compositions of phenylquinoline carboxylic acids |
US4900775A (en) * | 1988-02-29 | 1990-02-13 | Gaf Chemicals Corporation | Solubilization of complexes of water-insoluble organic compounds by aqueous solutions of polyvinylpyrrolidone |
-
1991
- 1991-03-14 HU HU84191A patent/HU206975B/en not_active IP Right Cessation
-
1992
- 1992-03-13 WO PCT/HU1992/000013 patent/WO1992016209A1/en not_active Application Discontinuation
- 1992-03-13 EP EP19920906850 patent/EP0575439A1/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2049420A (en) * | 1979-04-10 | 1980-12-31 | Riker Laboratories Inc | Veterinary medicament based on benxoquinolizine carboxylic acids and their derivatives |
EP0100168A2 (en) * | 1982-07-06 | 1984-02-08 | Alan George Rogerson | Processes for preparing tablets by a modified 'wet-granulation' technique |
WO1987003509A1 (en) * | 1985-12-10 | 1987-06-18 | Cerwen Erik Audunn | Method for the assembly of polar-nonpolar-polar proteolipid membranes |
EP0261426A1 (en) * | 1986-08-28 | 1988-03-30 | The Du Pont Merck Pharmaceutical Company | Freeze-dried pharmaceutical compositions of phenylquinoline carboxylic acids |
US4900775A (en) * | 1988-02-29 | 1990-02-13 | Gaf Chemicals Corporation | Solubilization of complexes of water-insoluble organic compounds by aqueous solutions of polyvinylpyrrolidone |
Non-Patent Citations (1)
Title |
---|
PATENT ABSTRACTS OF JAPAN, unexamined applications, Field C, Volume 4, Number 190, 26 December 1980 (26.12.80), The Patent Office Japanese Government, page 90 C 37; & JP,A,55 129 220 (YAMANOUCHI SEIYAKU K.K.). * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997009036A2 (en) * | 1995-09-01 | 1997-03-13 | Euro-Celtique S.A. | Improved pharmaceutical ion exchange resin composition |
WO1997009036A3 (en) * | 1995-09-01 | 1997-04-24 | Euro Celtique Sa | Improved pharmaceutical ion exchange resin composition |
US6077532A (en) * | 1995-09-01 | 2000-06-20 | Euro-Celtique, S.A. | Pharmaceutical ion exchange resin composition |
Also Published As
Publication number | Publication date |
---|---|
HU206975B (en) | 1993-03-01 |
HU910841D0 (en) | 1991-09-30 |
EP0575439A1 (en) | 1993-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1117013A (en) | Method for treating kidney stones | |
CA1320192C (en) | Pharmaceutical compositions | |
EP2062581B1 (en) | The antibiotics composition comprising beta-lactam antibiotics and ionic chelating agents | |
KR100696350B1 (en) | Immediate Release Tablet | |
US5334582A (en) | Pharmaceutical bacteriocin compositions and methods for using the same | |
US4956386A (en) | Pharmaceutical compositions and process for their preparation | |
US4724148A (en) | Amosulalol hydrochloride long acting formulation | |
KR100344479B1 (en) | How to stabilize carbapenem antibiotics | |
EP1294372B1 (en) | Dry powder formulation comprising racecadotril | |
CA2127987C (en) | Pharmaceutical bacteriocin compositions | |
EP1142573B1 (en) | Pharmaceutical compositions comprising faropenem sodium and a diamineacetate compound for improving gastrointestinal absorption | |
US4950653A (en) | Solid iodophor composition | |
EP0593573A1 (en) | Pharmaceutical formulation of a beta-lactam antibiotic and clavulanic acid or a water-soluble salt thereof | |
US7601347B2 (en) | Methods and compositions for controlled release of bioactive compounds | |
EP0782443A1 (en) | Pharmaceutical formulations comprising clavulanic acid or derivatives and an organic acid or salt | |
WO1992016209A1 (en) | Granules and veterinary compositions comprising a water-soluble complex of flumequine | |
WO2001045667A2 (en) | Water-soluble powders for oral solution and use thereof | |
JP2020528426A (en) | Lactofericin and lactoferrampin for the treatment of infectious diseases | |
WO1997019690A1 (en) | Stable vancomycin hydrochloride solutions | |
US20060275363A1 (en) | Stable granulates containing s-adenosylmethionine and process for preparation thereof | |
CN1105563A (en) | Antibiotic combination | |
US7244720B2 (en) | Soluble forms of amoxicillin and treatment of animals | |
FR2530467A1 (en) | PROGRESSIVE DISPENSING ELEMENT OF ACTIVE SUBSTANCES, PROCESS FOR PRODUCING THE SAME, AND COMPOSITION FOR MANUFACTURING THE SAME | |
EP0293975B1 (en) | Dry, rapidly soluble, compositions of beta-lactam antibiotics | |
WO1994008594A1 (en) | Pharmaceutical composition containing an antimicrobial agent and an antibiotic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CS RU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) |
Ref country code: UA |
|
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication |
Ref country code: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992906850 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992906850 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992906850 Country of ref document: EP |